Biotechnology

Science that shapes growth

 BIOTECHNOLOGY ADVANTAGE
SECTOR OVERVIEW INDIA
CURRENT SCENARIO ACCESSIBILITY
Over
CURRENT MARKET SIZE:
USD 200 Bn
USD 51 Bn (2018) to be spent on medical infrastructure in the next decade
Over
INDIA’S RANKING 1,60,000 hospital beds
expected to be added each year in the next decade
India is the India is among the
3rd largest top 12 destinations
biotech destination in the for biotechnology in the world,
Asia Pacific Region with approximately 3% share in
the global Biotechnology industry AFFORDABILITY
India has the Biotechnology revenues reached
second highest USD 11.6 Bn in 2017 Rising income could drive
number of US Food & Drug
Administration (USFDA)- India has
73 Mn households to the middle class over the next 10 years
approved manufacturing
plants outside the US 2600+ DPIIT recognized Over
biotechnology startups 650 Mn
people are expected to be covered by health insurance by 2020
MAJOR SEGMENTS The National Health Protection Scheme is the largest government
Bio-pharmaceuticals, The Department of Biotechnology funded healthcare program in the world, which is expected to benefit
Bio-services, Bio-agri launched the first ever Industry-Academia
mission to accelerate bio-pharmaceutical
100 Mn poor families in the country
by providing a cover of up to INR 5 lakh (~USD 6900)
development in India under the per family per year for secondary and tertiary care
‘National Biopharma Mission’ in June 2017

FUTURE POTENTIAL Availability of affordable medicines under the

Pradhan Mantri Bhartiya
Janaushadhi Pariyojana(PMBJP)
has led to savings worth INR 1000 Cr (~USD 138 Mn)
By 2025, the Indian
biotechnology industry is Focus states: for Indian citizens till date
expected to reach Gujarat, Telangana, Andhra Pradesh,
Karnataka, and Himachal Pradesh
USD 100 Bn
2 3
 ADVANTAGE POLICY SUPPORT
INDIA & INCENTIVES
SKILLED HUMAN CAPITAL FDI POLICY
100% under automatic route for greenfield projects
India has a population of 100% under government route for brownfield investments
1.3 Bn 74% under automatic route for brownfield investments
with 50% under the age of 25 which contributes to
a young and affordable high-quality skilled workforce
SKILL DEVELOPMENT
Recent development of several life-science clusters builds Setting up of the Life Sciences Sector Skill Development
collaborations between research institutes and the private sector, Council (LSSSDC) under National Skill Development
growing the R&D capabilities Corporation (NSDC) to promote skill development in the
life sciences sector

The government has come up with an industry-academia

collaboration with the World Bank for accelerating
Discovery research for early-development of biopharmaceuticals STATE-SPECIFIC POLICIES
Andhra Pradesh launched its Biotechnology Policy 2015-2020,
which has enabled the development of multiple infrastructure
projects and industrial parks and has helped the state
INFRASTRUCTURE FACILITIES to become a top biotech destination in India

Gujarat ts draft Biotechnology Policy 2016-2021 with the aim to

develop a robust biotechnology ecosystem in the state
Central and state governments have worked
to set up several incubators and life-science Rajasthan launched Biotechnology Policy 2015 with the aim to
clusters across India establish world class research institutes and
biomanufacturing infrastructure
9 DBT-supported Biotech Parks Telangana launched the Life Sciences Policy 2015-2020,
41 BIRAC-supported Bio-incubators which has helped Telangana develop suitable infrastructure to
attract global life science companies and become a leading
invesment destination in the field

EPIDEMIOLOGICAL FACTORS Uttarakhand launched its Biotechnology Policy 2018-2023 with the
aim to attract new investments worth INR 5000 Cr in the sector as well
as generate employment opportunities for 5000 people by 2023
Patient pool expected to increase over 20% in the next
Himachal Pradesh launched its Biotechnology Policy 2014 with the
10 years, aim to make Himachal a globally competitive destination for the
development of biotechnology products, processes and services
mainly due to rise in population
Assam Biotechnology Policy 2018-2022 was recently launched to
New diseases & lifestyle changes develop the biotechnology industry in Assam, which currently has
to boost demand for drugs and devices an emerging BioAgri segment

4 5
 STARTUP
STATE-SPECIFIC POLICIES
Karnataka Biotechnology Policy 2017-2022 lays emphasis on
ECOSYSTEM
strengthening the ecosystem required to boost startups, providing
access to funds for R&D and product development, developing
attractive incentives for investors, and providing mentorship for CURRENT SCENARIO
further growth of the biotechnology sector in Karnataka
Odisha Biotechnology Policy 2018 was launched with the aim of
making Odisha one of the top biotech investment and innovation
destinations in the country India has robust startup ecosystem which comes from gradual improvements
in the ease of doing business, proof-of-concept funds for startups
Madhya Pradesh Biotechnology Policy 2003 looks at the conservation and favorable government policies
and sustainable utilization of bio-resources to promote
socio-economic growth in the state BIRAC will continue to grow its partnerships with innovative foundations
and universities to focus on Make in India and Startup India programs

BIRAC
Biotechnology Industry Research Assistance Council (BIRAC) is a
not-for-profit set up by Department of Biotechnology (DBT),
Government of India as an interface agency to strengthen and
empower the emerging biotechnology enterprises to undertake
strategic research and innovation
Biotechnology Industry Facilitation Cell for Make in India at BIRAC
Sector-wise representation
of startups
MAJOR BIOTECH INITIATIVES
Regulations and guidelines on biosafety of recombinant DNA
research & biocontainment released (2017)
The Lok Sabha has passed the DNA Technology (Use and Application)
Regulation Bill, 2018 that allows regulated use of DNA
Innovate in India" (2017) - a DBT and World Bank program, with a 17%
funding of USD 250Mn- aims to bring together industry and
academia to promote entrepreneurship and indigenous BioPharma
manufacturing in bio-pharma
7% BioAgri
THE NEW DRUGS AND 6% BioIndustry
CLINICAL TRIALS RULES, 2019 62%
BioIT
The Ministry of Health and Family welfare released the new rule to 8%
promote clinical research in the country
BioResearch
Under it, drug approval outcomes must be shared within 30 days for a
clinical trial done within India, and 90 days for clinical trials of drugs
developed outside India
Earlier, approval durations were a challenge as it could take anywhere
from 6-12 months

6 7
 KEY SEGMENTS
Biotechnology Segments 1 BIOPHARMACEUTICALS
1.1 BIO-SIMILARS
Biologics are expected to contribute approximately
27%
to global prescription sales by 2020. Given the immense
growth of Biologics, the opportunity for biosimilars is
evident- and has attracted high investments. The size of the
01% global biosimilar market is predicted to reach
04%
USD 25 Bn
by 2020

15% India Opportunity:

India has 50+ approved biosimilar products, with a market
size of USD 0.92 Bn in 2016. The Indian market for biosimilars
is expected to reach
USD 2.2 Bn
by 2025
62%
18% Approximately
USD 70 Bn
biologics drugs will go off- patent between 2016 and 2020,
presenting a significant opportunity for exports

1.2 VACCINES
Globally, vaccines are a
USD 30 Bn
market. The Indian vaccine market is valued close to USD 3 Bn,
with two-thirds of this exported. With a projected growth rate of
10-15% over the next decade, the Indian vaccine market has the
potential to become a USD 8-12 Bn industry by 2025

India Opportunity:
India currently exports vaccines to about
BIOPHARMACEUTICALS 150 countries
BIO-SERVICE India meets
BIO-AGRICULTURE
40-70%
of the World Health Organisation (WHO) demand for the DPT
(diphtheria, pertussis or whooping cough, and tetanus) and
BIO-INDUSTRIALS BCG (Bacille Calmette-guérin) vaccines against tuberculosis,
as well as almost 90% of its demand for the measles vaccine
BIO INFORMATICS, SYSTEM BIOLOGY

8 9
 2
1.3 INSULIN
Globally diabetes is one of the most prevalent disorders.
India has the largest pool of diabetic patients, with more than
41 Mn people suffering from the disease. It is estimated that BIO-SERVICES
India will have more than
100 Mn
diabetics by 2030
2.1 CONTRACT MANUFACTURING
India Opportunity:
The global market for Contract Manufacturing is estimated at
USD 4 Bn and is expected to reach USD 8.8 Bn by 2025. India
has been a major player in contract manufacturing
The direct and indirect costs of treating such patients are with USD 1.3 Bn market. Indian Contract Manufacturing
currently about US$420 per person per year. If these costs market is expected to grow to
remained the same as they are now, India’s total bill for USD 4 Bn
diabetes would be about by 2025
USD 30 Bn
by 2025
India Opportunity:
The global anti-diabetes market is worth more than India has a far superior edge, due to resources including
USD 50 Bn growing at approximately 15% of manpower, technically knowledgeable work force,
which insulin is close to USD 30 Bn and is WHO-GMP approved production premises and a
expected to reach substantial 40% lower cost of operation and production
USD 57 Bn
by 2025

1.4 REGENERATIVE MEDICINE 2.2 CLINICAL RESEARCH

Global contract research market is estimated at approximately
The regenerative medicine market can be categorized into USD 340 Bn and is expected to reach
three major categories: tissue engineering, biomaterials/
biomolecules, and stem cell therapy. Rise in the prevalence USD 45 Bn
of chronic disease is driving the demand for regenerative by 2025
medicine
India Opportunity:
India Opportunity:
50%
Several major research institutes, such as the National Centre public funding through a public private partnership (PPP)
for Biological Sciences in Bangalore, the Centre for Cellular and model to harness India’s innovation capability
Molecular Biology in Hyderabad the National Centre for Cell
Sciences in Pune and the National Brain Research Centre near Vision 2020 to catapult India into one of the
Delhi, are investigating the use of stem cells to regenerate top five
nerve, heart and adult muscle cells, and repair damaged bone
tissue Pharma innovation hubs by 2020 with one out of every
5 to 10 drugs discovered worldwide, coming from India
The Indian Council of Medical Research has issued National
Guideline for Stem Cell Research (2017) to promote clinical
applications of stem cell research in ophthalmology,
cardiology and spinal cord repair, and build links between
scientists and doctors

10 11
 3
4.2 Enzymes (Industrial + Specialty)
Globally North America and Europe together form more
BIO-AGRICULTURE than 60% of the Enzymes’ market. Indian market is
relatively small and contributes approximately 2%
of the overall enzymes market
The global market for Bio-Agriculture is expected to grow
from USD 20 Bn to India Opportunity:
USD 59 Bn
by 2025 with USD 43 Bn contributed by genomic based India imports about
products. Bio-Agriculture in India at USD 11 Bn (2018) forms 70%
the third largest and fastest growing segment within the of the total enzyme consumption
industry. The segment comprises primarily of hybrid seeds,
GM crops, bio-fertilizers and bio-pesticides The industrial enzymes segment, has an estimated worth of
USD 75 Mn,
India Opportunity:
and is a quickly growing market in India. Pharmaceutical
enzymes are the represents most of the industrial
enzyme demands in India and cover almost 50% of the
India ranks total enzyme demand, followed by detergent enzymes
5th (20%) and textile enzymes (20%)
in global cultivation of GM crops

4
4.3 BIO-POLYMERS
The global biopolymers market is expected to grow at a
CAGR of 16.47% between 2019-2025

BIO-INDUSTRIALS India Opportunity:

4.1 BIO-FUELS India generates
33.1 Mn pounds
Globally, biofuels have caught the attention in last decade
of plastic waste each day of which only 19.8 Mn pounds is
and it is imperative to keep up with the pace of developments
collected and recycled. 18 states including Maharashtra,
in the field of biofuels. Bio-fuels are of strategic importance
Karnataka, Andhra Pradesh, Goa, Rajasthan,
for India. It can help meet multiple objectives viz., energy
Tamil Nadu, and now Madhya Pradesh have introduced a
security, oil import substitution, cleaner environment and
ban on disposable plastic
rural employment

India Opportunity:
India has largest arable land after US which makes raw
material availability relatively easy. Need of the hour is to
create and commercialize cost efficient, carbon neutral
technologies which can leverage the natural resources
available

National Policy on Biofuels, 2018, indicates a viability gap

funding scheme for Second Generation ethanol Bio refineries of
INR 5000 Cr
in 6 years in addition to additional tax incentives, higher
purchase price as compared to First Generation biofuels

12 13
 5 BIO-IT
5.1 BIO-INFORMATICS, GENOMICS
KEY
STAKEHOLDER
& PRECISION MEDICINE
Globally, the bioinformatics market is expected to grow from
USD 7.5 Bn in 2018 and is expected to generate around Department of Biotechnology,
USD 19.8 Bn Ministry of Science & Technology
by 2025, at a CAGR of around 14.9% between 2019 and 2025.
Major growth drivers include the need for integrated database,
increased government initiatives and funding, growing use of
bioinformatics in drug discovery and biomarker development
and rising interest in genomics and proteomics
Department of Science and Technology,
India Opportunity: Ministry of Science and Technology
Bioinformatics is one of the fastest growing segments in the
biotechnology sector of India with over
200 companies
in Bangalore, Delhi, Hyderabad, Pune and Chennai
Biotechnology Industry Research
Increase in public funding towards research and development
along with increasing investments from private companies Assistance Council (BIRAC)

5.2 BIG DATA

Big Data analytics will transform the biopharma industry, reinforcing
the promise of big data for the emergence of personalized medicine Council of Scientific and Industrial
and genomics, unprecedented levels of data sharing and collaboration,
advances in technology and availability of data scientists Research (CSIR)

India Opportunity:
The Government of India has helped the development of
high-performance computing technology for use in bioinformatic
Association of Biotechnology
India is a leader in IT Outsourcing, with Led Enterprises (ABLE)
700,000 graduates
and approximately 300,000 post graduates passing out in science and
mathematics. India can address the global big data resource requirement
As India is home to 1.3 Bn people and consists of more than 4500
anthropologically well-defined populations, the genetic diversity is 4x greater Central Drugs Standard Control
than Europe. This offers a huge opportunity for India to create and mine a rich Organization (CDSCO),
source of genomic information. India is also rich with regards to genetic
resources of medicinal and aromatic plants as it constitutes 11% of total Ministry of Health and Family Welfare
known world flora, bringing a huge IT-enabled data mining advantage

14 15
 INDUSTRY
CLUSTERS/ ZONES
Indian Life
Science
Cluster
Map
DBT supported biotechnology parks and incubation centers locat-
ed in different states for the promotion of Biotech start-up compa-
nies and the promotion of Public Private Partnerships
Biotech Park, Lucknow, Uttar Pradesh
Biotechnology Incubation Centre, Hyderabad, Telangana
Tidco Centre For Life Sciences (TICEL) Biotech Park, Chennai, Tamil Nadu
The Golden Jubilee Biotech Park For Women, Chennai, Tamil Nadu;
Biotech Park Technology Incubation Centre, Guwahati, Assam;
Biotechnology Incubation Centre, Cochin, Kerala;
Biotechnology Park, Bangalore, Karnataka;
Industrial Biotechnology Parks (IBTPs), Jammu & Kashmir; and
Map not to scale
Chhattisgarh Biotech Park, Naya Raipur, Chhattisgarh
Lucknow: Chennai:
• CDRI, IITR, CIMAP, NBRI • Anna University
• Lucknow Biotech Park • IIT Madras
• TICEL Biotech Park
New Delhi: • Women’s Biotech Park
Operational • DBT, DST, CSIR, DP, ICMR, ICAR
Biotech • Translational Health Sciences Cluster Vadodhara:
Parks
JOGINDER NAGAR
SHIMLA • National Institute of Immunology • PERD, NIPER
CHANDIGARH
• ICGEB • Savli Biotech Park
• Institute of Genomics & Integrative Biology • Proposed Biotech Park in Ahmedabad
SOHNA
• National Brain Research Center • MS University, Baroda
JAIPUR
ALVAR
• JNU, Delhi University
JODHPUR

Kolkata: Mumbai:
GANDHINAGAR
• Indian Inst. of Chemical Technology • TIFR
JAMNAGAR
VADODARA MIDNAPORE • Centre for Cellular & Molecular Biology • IIT Bombay, University of Mumbai
ANAND
BHUBANESWAR • Centre of DNA Fingerprinting & Diag. • National Chemical Lab
AURANGABAD KONARK
• National Institute of Nutrition, ICRISAT • National Center for Cell Sciences
PUNE
• University of Hyderabad, Osmania • Pune University, IISER
HYDERABAD • IKP Knowledge Park, SP Biotech Park • International Biotech Park
VISAKHAPATNAM
• AIBA, FABA
Hyderabad:
KARWAR
Bengaluru: • Indian Inst. of Chemical Technology
BENGALURU • Indian Institute of Science • Centre for Cellular & Molecular Biology
• Centre of DNA Fingerprinting & Diag.
CHENNAI
PUDUCHERRY • National Center for Biological Sciences
• JN Center for Advanced Scientific Research • National Institute of Nutrition, ICRISAT
KOCHI MADURAI
• University of Agriculture Sciences • University of Hyderabad, Osmania
• Stem Cell Institute • IKP Knowledge Park, SP Biotech Park
• IBAB, ABLE • AIBA, FABA
16 Map not to scale 17
 UPCOMING RECENT
PROJECTS INVESTMENTS
Hyderabad Pharma City: One of the biggest Pharma City cluster The drugs and pharmaceuticals sector attracted cumulative FDI inflows worth
projects in the world. The cluster aims to create a smart ecosystem, USD 16.73 Bn between April 2000 and June 2019, accounting for 4% of the total
setting a benchmark for sustainable industrial cities worldwide. FDI inflows into India
With plug-n-play facilities, the cluster is designed to become
the jump-start platform for companies that make bulk drugs, Major investments include:
fermentation products, synthetic drugs, intermediates, vitamins,
vaccines, drug formulations, nutraceuticals, herbal products, Piramal Enterprises Ltd acquired a portfolio of spasticity and pain management
specialty chemicals and cosmetics drugs from UK-based specialty biopharmaceutical company Mallinckrodt
Pharmaceuticals, in a deal worth USD 171 Mn (January 2017)
The Government of Uttar Pradesh is planning on setting up
six pharma parks in Noida, Bundelkhand, Ghaziabad, Gorakhpur,
Aurobindo Pharma Ltd has acquired four biosimilar products from Swiss firm
Lucknow and Allahabad
TL Bio-pharmaceutical G which will require TL Biopharmaceutical to supply all
the developmental data for four molecules, to be commercialized by
Construction of a new Odisha Biotech Park at Andharua, Aurobindo pharma (February 2017)
Bhubaneswar is also underway
Capital International Group, a PE equity fund, has acquired 3% stake in Intas

KEY PLAYERS
Pharmaceuticals Ltd from ChrysCapital Llc for a consideration of USD 107 Mn
(August 2017)

IN INDIA
Siemens Healthineers, which provides medical solutions and operates as a
subsidiary of Germany-based Siemens, has opened a new diagnostics
manufacturing facility in Vadodara, India. The 3150 Sq m facility is equipped
with a bench-marked manufacturing facility and globally renowned processes
and systems for Indian healthcare industry. The facility will manufacture
urine strips and autopak kits (August 2018)
Top Indian Biotech Companies:
Germany-based pharmaceutical group Merck KGaA has signed a memorandum of
Company CEO Revenue(USD Mn 2018) understanding with India-based CSIR-Institute of Microbial Technology to open a
Biocon Kiran Mazumdar Shaw 590 'High-End Skill Development Centre' in Chandigarh, India. The centre will help
accelerate healthcare research and train local students and researchers in the
Serum Institute of India Cyrus Poonawala 590
latest life science technologies (November 2018)
Panacea Biotec Limited Sandeep Jain 65.40
Dr. Reddy’s Laboratory Limited G.V Prasad 2100 German chemical and pharma major, Bayer AG completed the integration
of Monsanto's India business to form Bayer CorpScience Ltd as part of a
Wockhardt Murtaza Khorakiwala 560
USD 63 Bn mega deal (September 2019)
Jubilant Life Sciences Co Shyam S Bhartia 1053
Bharat Serums and Vaccines Limited Bharat V. Daftary 98
Indian Immunologicals Limited K. Anand Kumar -

18 All information in this brochure was last updated on Apr 30th, 2020. 19
 INVEST INDIA



HOW WE HELP INVESTORS

RESEARCH CONTENT POLICY ADVISORY/ STAKEHOLDER SITE

PROVIDED REPRESENTATION MEETING VISITS

LOCATION ISSUE REGULATORY

ANALYSIS RESOLUTION CLEARANCE FACILITATION

To find out more

https://www.investindia.gov.in/sector/biotechnology

Phone No: 011 2304 8101

Email ID: biotech@investindia.org.in

First Floor,
Vigyan Bhawan Annexe,
Maulana Azad Road, New Delhi - 110011

@investindia @invest-india @investindiaofficial